For research use only · Not for human consumption
This material is reference information for laboratory study of research peptides. It is not medical advice and it is not instructions for human use, self-administration, or therapeutic application. Capital Peptides supplies research chemicals for in-vitro and animal-model study only. Discuss any health-related questions with a licensed medical practitioner.
ℹ️ Note: Most published peptide research uses male subjects. Female-specific data is limited. This guide synthesises the available evidence and physiological reasoning — it is not a substitute for individualised medical advice.
1. Dosing differences
Women generally benefit from lower doses than the ranges established in predominantly-male research populations. Contributing factors:
- Lower average body weight. Most research dose ranges are established in 70–90 kg male subjects. Body-weight-based scaling suggests lower absolute doses for most women.
- Hormonal differences. Oestrogen and progesterone interact with GH signalling pathways. Women naturally have more frequent GH pulses but lower amplitude. GH secretagogue response may be different.
- Receptor sensitivity differences. Some evidence suggests women may be more sensitive to GH-axis compounds — meaning lower doses produce equivalent effects.
| Compound class | Male starting dose | Suggested female starting dose |
|---|---|---|
| GH secretagogues (CJC, Ipa) | 100–200 mcg 1–2x/day | 50–100 mcg 1–2x/day — titrate up based on response |
| BPC-157 | 500 mcg/day | 250–500 mcg/day — body weight scaled |
| TB-500 | 5–10 mg/week | 2.5–5 mg/week |
| GLP-1 agonists | Same as male protocols | Same — no sex-specific dose differences in approved use |
| Cognitive peptides (Semax, Selank) | 300–600 mcg/day | 150–300 mcg/day initially |
💡 Tip: Start at the lower end and titrate. Many women find effective doses well below the standard male ranges. There is no benefit to starting higher — only increased side effect risk.
2. Hormonal interactions
The female hormonal environment affects and is affected by several peptide classes:
| Interaction | Detail |
|---|---|
| GH and oestrogen | Oestrogen modulates GH secretion and IGF-1 levels. Post-menopausal women have lower endogenous GH — GH secretagogues may have more pronounced effect. Women on exogenous oestrogen (HRT, OCP) may have blunted IGF-1 response. |
| GH and cortisol | Cortisol opposes GH action. Women with chronic stress or high cortisol may see reduced GH secretagogue efficacy. |
| Melanocortin peptides (PT-141) | PT-141 works via the same pathway in women as men — stimulates desire via central melanocortin signalling. Approved for HSDD (hypoactive sexual desire disorder) in pre-menopausal women under brand name Vyleesi. |
| GHK-Cu (cosmetic applications) | Widely used by women for skin quality improvement. Topical application — no significant hormonal interaction at cosmetic doses. |
| GLP-1 agonists and menstrual cycle | No known direct effect on menstrual cycle regularity at research doses. May affect appetite and weight, which can secondarily affect cycle regularity in underweight individuals. |
3. Menstrual cycle considerations
There is very limited research on timing peptide protocols relative to the menstrual cycle. Practical considerations:
- GH sensitivity varies across the cycle. Oestrogen enhances GH pulse amplitude in the luteal phase (second half of cycle). This may mean variable response to GH secretagogues across the month.
- Water retention compounds with GH-related retention. The luteal phase naturally causes fluid retention — adding GH secretagogue water retention on top can be more pronounced in the week before menstruation.
- No specific contraindication to any phase. There is no evidence that any particular cycle phase is unsafe for peptide administration.
- Track carefully. If using a menstrual tracking app alongside your peptide journal, you may identify personal patterns in response that are difficult to see without the data.
4. Peptides commonly used by women
| Peptide | Common female application |
|---|---|
| BPC-157 | Injury repair, gut health, inflammation — no sex-specific considerations |
| GHK-Cu (topical) | Skin elasticity, collagen, anti-ageing — widely used topically |
| GHK-Cu (sub-Q) | Systemic anti-ageing, collagen support |
| Ipamorelin / CJC-1295 | Body composition, recovery, sleep quality |
| Semaglutide / Tirzepatide | Weight management — extensively studied in women; evidence base is strong |
| PT-141 | Low libido — specifically studied and approved for HSDD in women |
| Semax / Selank | Cognitive clarity, stress resilience, anxiety |
| Epithalon | Anti-ageing protocols; some evidence for telomere-related effects |
5. Special cautions for women
- Pregnancy: Do not use any research peptide during pregnancy. No exceptions. See when not to use.
- Breastfeeding: Avoid all research peptides. Transfer to breast milk is unstudied.
- History of hormone-sensitive cancer (breast, ovarian, endometrial): Avoid GH-axis peptides. Discuss any peptide use with your oncologist.
- Women on hormonal contraception: OCP can suppress GH axis response — may reduce GH secretagogue efficacy. Not a safety concern; adjust expectations.
- Women undergoing fertility treatment: Avoid GH-axis and immune-modulating peptides during IVF cycles without specific medical guidance — interactions with ovarian stimulation protocols are unstudied.